2023-03-14 07:49:52 ET
- Ainos ( NASDAQ: AIMD ) signed an agreement with Taipei-listed Merdury Biopharmaceutical to explore a phase 3 trial of Veldona to treat oral warts in patients who are HIV-seropositive.
- Under the Memorandum of Understanding (MoU), the companies will evaluate the feasibility of Merdury's potential investment and participation in the completion of the phase 3 study of Ainos' drug Veldona to treat oral warts in patients who are HIV-seropositive.
- The companies will also explore Ainos' potential licensing of Merdury's new drug development platform technology, and cooperate to identify other partners to participate in approval and sale of Ainos' drug candidates.
- In addition, the two companies will also evaluate Merdury's capacity to help Ainos in developing new manufacturing processes.
- AIMD +80.56% to $1.30 premarket March 14
For further details see:
Ainos stock surges 80% on research pact with Merdury for Veldona